API development in multiple bottlenecks motivate enterprise innovation transformation

January 21, 2016

Source: xinhua

Xinhuanet Beijing on January 21st (GongXiaoQian) is API producer and exporter in China, the drugs manufacture any of the material or material mixture can be referred to as the active pharmaceutical ingredients. Learned, active pharmaceutical ingredients on the one hand to make our country enterprise obtained the considerable profits, on the other hand also left excess capacity, environmental protection pressure, and many other problems. Already one step ahead ", some of the API enterprises, optimize the industrial layout and the allocation of resources, the API production and formulation development strategic transformation." Recently, the Chinese chemical pharmaceutical industry association executive director Pan Guangcheng said in an interview with xinhua that transformation has become a major trend of pharmaceutical industry.

Multiple block API enterprise development bottleneck

It is reported, antibiotics, vitamin C and other bulk drug substances in our country export accounts for absolute advantage in the world. But because the domestic API industry scale expands unceasingly in recent years, our country is common API low level repeated construction, overcapacity problem is outstanding, cause the low price competition and the waste of resources, and form a vicious circle.

In addition, our API enterprises have faced with the lingering problems - environmental pressure. Especially on January 1, 2015 the implementation of new environmental laws, strengthening illegal punishment of the enterprise, it has a considerable effect on API enterprises.

"As countries a series of policies issued, active pharmaceutical ingredients industry scale and cost advantages of relying only on the past, it is difficult to maintain sustained and healthy development of enterprises." The personage inside course of study says, past drug firms focusing on the problem such as production capacity, price, and now had to technology innovation, quality improvement and change of the high-end market development.

Pan Guangcheng pointed out that the plight, API enterprises need to constantly adjust the industrial structure, increase the high added value, small pollution products.

Leading enterprise innovation transformation to upgrade

In recent years, in order to better development, the domestic part of the mainstream API companies all show, intensify business from various angles. It is reported that zhejiang pharmaceutical, nolato, group are currently active pharmaceutical ingredients such as production and export good enterprise development. From the point of the transformation of the current situation, has made good progress.

It is understood that in recent years, zhejiang pharmaceutical aggressively from API to transformation, according to the 2015 semi-annual report shows that although faced with countries such as the preparation products price reform, the influence of the new policy such as the drug bid, but because of the continued growth of sales, sales revenue during the reporting period year-on-year growth of 11.85%.

In addition, shiyao group, drive the innovation as the soul of enterprise development, promote the strategic transformation in recent years, that is, from API to innovation transformation. According to shiyao group performance in the third quarter of 2015, the main innovation medicine business sales in period continue to maintain rapid growth, overall revenue about hk $2.729 billion, an increase of 35.1%.

Shiyao group, officials said on the API section development direction, the excess capacity, energy intensive and highly polluting, cannot improve upgrade products for a long time, take the initiative to withdraw from the competition; For modification, can make use of modern technology, in the long run there is a market for products, actively to upgrade, reduce costs, increase scale, expand market share, make it become the sustainable profitable products, enhance the core competitiveness of the enterprise.

Under the market orientation of the transformation, the API enterprise income will increase. According to the Chinese chemical pharmaceutical industry association is expected, according to data in 2015, the chemical pharmaceutical business owners operating income of 1.15 trillion yuan, the API business owners operating income of 455.8 billion yuan, up 10.07% from a year earlier, chemical medicine preparations, the main business income is 694.2 billion yuan, up 9.14% from a year earlier.

"In the new market environment, a set of data in the whole industry in China, 2015 API are to the right direction." Pan Guangcheng said, but as a large nation of active pharmaceutical ingredients, slightly lacking in terms of formulation development in our country, the increase of production and research and development is still the important topic at present.

Enterprises need to internationalization road in the future

Along with our country to the attention of the medical field, the state introduced gradually medical policy, medical industry overall technical strength is also improved.

"2016 is the starting year." much starker choices-and graver consequences-in "development planning from the point of chemical pharmaceutical industry, further defined 'much starker choices-and graver consequences-in industry development ideas and development focus, good start, a good step, is very important." Pan Guangcheng advice, from the perspective of government, first of all, promote enterprise development API, dissolve the excess capacity to market forces, the government needs to reduce interference, make enterprise can independently discover problems, find business opportunities, and independent development. Second, the government needs to strengthen the enterprise's information guidance, to strengthen policy support to enterprises, especially in the aspect of environmental protection investment subsidies to some excellent enterprises. From the point of enterprise, first, to compress the bulk API production overcapacity, through mergers and acquisitions to improve concentration, we should encourage strong enterprises improve the industrial chain, optimizing the allocation of resources; Second, special API will be focus on the development of a direction in our country, enterprises need to develop characteristic active pharmaceutical ingredients, promote production specifications and product quality in line with international standards, promote the international certification of characteristics of active pharmaceutical ingredients, expand exports; Third, the development of new technology of active pharmaceutical ingredients, increase the intensity of API enterprise environmental comprehensive harness, to raise the level of industry clean, strengthen pollution management, improve the level of recycling; Fourth, enterprises to speed up the introduction and training international talents and mastering foreign legal and market environment, accelerate the international registration and production management system international certification, enrich the product line, improve the added value of exports preparation products.

"Future API enterprises must taking the path of internationalization, with the development of all the way ' 'area, API enterprises will have very good opportunities for development, enterprises to accelerate the speed of integratewith the world market, through the foreign factories to reduce excess capacity, enhance the international competitiveness of China's pharmaceutical industry, can be more advantageous to the enterprise development." Pan Guangcheng said.